Upsher-Smith Laboratories, LLC, a United States-based pharmaceutical company, announced on Thursday that it has introduced Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, an AB-rated generic equivalent to the branded product Combigan.
This product launch is a result of Upsher-Smith's strategic partnership with RAFARM UK that includes the development and distribution of six ophthalmic and otic ANDA products.
According to IQVIA, the brimonidine tartrate and timolol maleate ophthalmic solution market had United States sales of around USD392m for the 12 months ending February 2023.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream